ARTICLE
|
doi:10.20944/preprints202406.0122.v1
Subject:
Medicine And Pharmacology,
Oncology And Oncogenics
Keywords:
Tissue agnostic drug development; Pembrolizumab; Microsatellite instability-high (MSI-H); Tumor mutational burden-high (TMB-H); Dostarlimab-gxly; Larotrectinib; Entrectinib; Neurotrophic tyrosine kinase (NTRK); Dabrafenib and trametinib; V-Raf Murine Sarcoma Viral Oncogene Homolog B V600E (BRAFV600E); Selpercatinib; Rearranged during transfection (RET); Precision oncology.
Online: 3 June 2024 (16:08:38 CEST)